[Highlights of the guidelines of prevention and treatment for hepatitis C (2019 version)].

Abstract

The key points from the updated guideline of prevention and treatment for hepatitis C (2019 version) is compared with the previous hepatitis C guideline. A new terminology and the World Health Organization's goal of eliminating viral hepatitis as a public-health threat by 2030 are stressed. In the prevention section, the screening for hepatitis C virus infection in high-risk population is the primary means of prevention, emphasizing that treatment, is prevention. In the aspect of treatment, pangenotypic interferon-free scheme are initial recommendations. In addition, it also introduces our country independent research and development on direct-acting antiviral agents, and antiviral therapy schedule for many special populations, including decompensated liver cirrhosis, chronic kidney disease, children and adolescents combined with chronic kidney injury, HBV infection-before and after liver transplantation, treatment failure, and acute hepatitis C. A simplified on-treatment monitoring schedule, especially genotype 3 prevalent in Southwest part of our country is introduced.

• Authors: H Y Rao, Z P Duan, G Q Wang, L Wei
• Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology (Zhonghua Gan Zang Bing Za Zhi) Vol. 28 Issue 2 Pg. 129-132 (Feb 20 2020) ISSN: 1007-3418 [Print] China
• PMID: 32164062 (Publication Type: Journal Article)

Chemical References

• Antiviral Agents
• Interferons

Topics

• Adolescent
• Antiviral Agents (therapeutic use)
• Child
• Evidence-Based Medicine
• Guidelines as Topic (standards)
• Hepacivirus (drug effects, isolation & purification)
• Hepatitis C (diagnosis, drug therapy, prevention & control)
• Humans
• Interferons (therapeutic use)
• Liver Cirrhosis
• Practice Guidelines as Topic
• Primary Prevention (methods)
• Treatment Outcome